The Role of ExtraVascular Transport
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 25 6403
Supporting Information Available: Experimental details and
characterization data for synthetic intermediates and BTOs 8–50.
Tables of physicochemical and in vitro data with estimates of errors.
This material is available free of charge via the Internet at http://
pubs.acs.org.
(22) Baker, M. A.; Zeman, E. M.; Hirst, V. K.; Brown, J. M. Metabolism
of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic
cytotoxicity. Cancer Res. 1988, 48, 5947–5952.
(
23) Priyadarsini, K. I.; Tracy, M.; Wardman, P. The one electron reduction
potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (Tirapazamine):
A hypoxia-selective bioreductive drug. Free Radical Res. 1996, 25,
93–399.
24) Daniels, J. S.; Gates, K. S. DNA cleavage by the antitumor agent
-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233). Evidence for
3
(
References
3
(
1) Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygen-
ation predicts radiation response in advanced squamous cell carcinoma
of the head and neck. Radiother. Oncol. 1996, 41, 31–39.
2) Fyles, A. W.; Milosevic, M.; Wong, R.; Kavanagh, M. C.; Pintilie,
M.; Sun, A.; Chapman, W.; Levin, W.; Manchul, L.; Keane, T. J.;
Hill, R. P. Oxygenation predicts radiation response and survival in
patients with cervix cancer. Radiother. Oncol. 1998, 48, 149–156.
involvement of hydroxyl radical. J. Am. Chem. Soc. 1996, 118, 3380–
3385.
(25) Anderson, R. F.; Shinde, S. S.; Hay, M. P.; Gamage, S. A.; Denny,
W. A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor
agents to oxidizing species following their one-electron reduction.
J. Am. Chem. Soc. 2003, 125, 748–756.
(26) Shinde, S. S.; Anderson, R. F.; Hay, M. P.; Gamage, S. A.; Denny,
W. A. Oxidation of 2-deoxyribose by benzotriazinyl radicals of
antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. J. Am. Chem. Soc.
2004, 126, 7853–7864.
(
(
3) Koukourakis, M. I.; Bentzen, S. M.; Giatromanolaki, A.; Wilson, G. D.;
Daley, F. M.; Saunders, M. I.; Dische, S.; Sivridis, E.; Harris, A. L.
Endogenous markers of two separate hypoxia response pathways
(hypoxia inducible factor 2 R and carbonic anhydrase 9) are associated
(
27) Jones, G. D. D.; Weinfeld, M. Dual action of tirapazamine in the
induction of DNA strand breaks. Cancer Res. 1996, 56, 1584–1590.
28) Siim, B. G.; van Zijl, P. L.; Brown, J. M. Tirapazamine-induced DNA
damage measured using the comet assay correlates with cytotoxicity
towards hypoxic tumour cells in vitro. Br. J. Cancer 1996, 73, 952–
with radiotherapy failure in head and neck cancer patients recruited
in the CHART randomized trial. J. Clin. Oncol. 2006, 24, 727–735.
4) Durand, R. E. The influence of microenvironmental factors during
cancer therapy. In ViVo 1994, 8, 691–735.
(
(
(5) Tannock, I. F. Conventional cancer therapy: Promise broken or promise
9
60.
delayed. Lancet 1998, 351 (Suppl 2), 9–16.
6) Brown, J. M.; Wilson, W. R. Exploiting tumor hypoxia in cancer
(
(
(
29) Siim, B. G.; Menke, D. R.; Dorie, M. J.; Brown, J. M. Tirapazamine-
induced cytotoxicity and DNA damage in transplanted tumors:
Relationship to tumor hypoxia. Cancer Res. 1997, 57, 2922–2928.
30) Daniels, J. S.; Gates, K. S.; Tronche, C.; Greenberg, M. M. Direct
evidence for bimodal DNA damage induced by tirapazamine. Chem.
Res. Toxicol. 1998, 11, 1254–1257.
(
(
(
(
treatment. Nat. ReV. Cancer 2004, 4, 437–447.
7) Harris, A. L. Hypoxia—A key regulatory factor in tumour growth.
Nat. ReV. Cancer 2002, 2, 38–47.
8) Semenza, G. L. HIF-1 and tumor progression: Pathophysiology and
therapeutics. Trends Mol. Med. 2002, 8, S62–S67.
31) Hwang, J.-T.; Greenberg, M. M.; Fuchs, T.; Gates, K. S. Reaction of
the hypoxia-selective antitumor agent tirapazamine with a C1′-radical
in single-stranded and double-stranded DNA: The drug and its
metabolites can serve as surrogates for molecular oxygen in radical-
mediated DNA damage reactions. Biochemistry 1999, 38, 14248–
9) Pennachietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano,
S.; Comoglio, P. M. Hypoxia promotes invasive growth by transcrip-
tional activation of the met protooncogene. Cancer Cell 2003, 3, 347–
3
61.
(
10) Cairns, R. A.; Hill, R. P. Acute hypoxia enhances spontaneous lymph
node metastasis in an orthotopic murine model of human cervical
carcinoma. Cancer Res. 2004, 64, 2054–2061.
11) Subarsky, P.; Hill, R. P. The hypoxic tumour microenvironment and
metastatic progression. Clin. Exp. Metastasis 2003, 20, 237–250.
12) Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors:
Opportunities (and problems) for cancer therapy. Cancer Res. 1998,
1
4255.
(
32) Wang, J.; Biedermann, K. A.; Brown, J. M. Repair of DNA and
chromosome breaks in cells exposed to SR 4233 under hypoxia or to
ionizing radiation. Cancer Res. 1992, 52, 4473–4477.
33) Siim, B. G.; Pruijn, F. B.; Sturman, J. R.; Hogg, A.; Hay, M. P.; Brown,
J. M.; Wilson, W. R. Selective potentiation of the hypoxic cytotoxicity
of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res.
(
(
(
5
8, 1408–1416.
2
004, 64, 736–742.
(
13) Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in
the design of bioreductive drugs. Br. J. Cancer 1996, 74, S32–S38.
14) Brown, J. M. SR 4233 (tirapazamine): A new anticancer drug
exploiting hypoxia in solid tumours. Br. J. Cancer 1993, 67, 1163–
(
(
34) Peters, K. B.; Brown, J. M. Tirapazamine: A hypoxia-activated
topoisomerase II poison. Cancer Res. 2002, 62, 5248–5283.
(
35) Doherty, N.; Hancock, S. L.; Kaye, S.; Coleman, C. N.; Shulman, L.;
Marquez, C.; Mariscal, C.; Rampling, R.; Senan, S.; Roemeling, R. V.
Muscle cramping in phase I clinical trials of tirapazamine (SR 4233)
with and without radiation. Int. J. Radiat. Oncol., Biol., Phys. 1994,
1
170.
(
15) Denny, W. A.; Wilson, W. R. Tirapazamine: A bioreductive anticancer
drug that exploits tumour hypoxia. Expert Opin. InVest. Drugs 2000,
2
9, 379–382.
9
, 2889–2901.
(
36) Durand, R. E.; Olive, P. L. Physiologic and cytotoxic effects of
(
16) Peters, L. J.; Rischin, D.; Hicks, R. J.; Hughes, P. G.; Sizeland, A. M.
Extraordinary tumor control in phase I trial of concurrent tirapazamine
cisplatin and radiotherapy for far advanced head and neck cancer. Int.
J. Radiat. Oncol., Biol., Phys. 1999, 45, 148–149.
17) Rishin, D.; Peters, L.; Hicks, R.; Hughes, P.; Fisher, R.; Hart, R.;
Sexton, M.; D’Costa, I.; von Roemeling, R. Phase I trial of concurrent
tirapazamine, cisplatin, and radiotherapy in patients with advanced
head and neck cancer. J. Clin. Oncol. 2001, 19, 535–542.
18) Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; Poulsen,
M.; Jackson, M.; Kenny, L.; Penniment, M.; Corry, J.; Lamb, D.;
McClure, B. Tirapazamine, cisplatin, and radiation versus fluorouracil,
cisplatin, and radiation in patients with locally advanced head and
neck cancer: A randomized phase II trial of the Trans-Tasman
Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 2005, 23,
tirapazamine in tumor-bearing mice. Radiat. Oncol. InVest. 1997, 5,
2
13–219.
(
37) Durand, R. E.; Olive, P. L. Evaluation of bioreductive drugs in multicell
spheroids. Int. J. Radiat. Oncol., Biol., Phys. 1992, 22, 689–692.
38) Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R.
Extravascular diffusion of tirapazamine: Effect of metabolic consump-
tion assessed using the multicellular layer model. Int. J. Radiat. Oncol.,
Biol., Phys. 1998, 42, 641–649.
(
(
(
(
39) Kyle, A. H.; Minchinton, A. I. Measurement of delivery and
metabolism of tirapazamine to tumour tissue using the multilayered
cell culture model. Cancer Chemother. Pharmacol. 1999, 43, 213–
2
20.
(
40) Baguley, B. C.; Hicks, K. O.; Wilson, W. R. Tumour cell cultures in
drug development. In Anticancer Drug DeVelopment; Baguley, B. C.,
Kerr, D. J., Eds.; Academic Press: San Diego, CA, 2002; pp 269–
7
9–87.
(
(
(
19) Le, Q.-T.; Taira, A.; Budenz, S.; Dorie, M. J.; Goffinet, D. R.; Fee,
W. E.; Goode, R.; Bloch, D.; Koong, A.; Brown, J. M.; Pinto, H. A.
Mature results from a randomized phase II trial of cisplatin plus
2
84.
(41) Hicks, K. O.; Pruijn, F. B.; Sturman, J. R.; Denny, W. A.; Wilson,
W. R. Multicellular resistance to tirapazamine is due to restricted
extravascular transport: A pharmacokinetic/pharmacodynamic study
in multicellular layers. Cancer Res. 2003, 63, 5970–5977.
5
-fluouracil and radiotherapy with or without tirapazamine in patients
with respectable stage IV head and neck squamous cell carcinomas.
Cancer 2006, 106, 1940–1949.
20) Rischin, D.; Hicks, R. J.; Fisher, R.; Binns, D.; Corry, J.; Porceddu,
(42) Hicks, K. O.; Siim, B. G.; Pruijn, F. B.; Wilson, W. R. Oxygen
dependence of the metabolic activation and cytotoxicity of tira-
pazamine: Implications for extravascular transport and activity in
tumors. Radiat. Res. 2004, 161, 656–666.
(43) Hicks, K. O.; Pruijn, F. B.; Secomb, T. W.; Hay, M. P.; Hsu, R.;
Brown, J. M.; Denny, W. A.; Dewhirst, M. W.; Wilson, W. R. Use of
three-dimensional tissue cultures to model extravascular transport and
predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl.
Cancer Inst. 2006, 98, 1118–1128.
18
S.; Peters, L. J. Prognostic significance of [ F]-misonidazole positron
emission tomography-detected tumor hypoxia in patients with ad-
vanced head and neck cancer randomly assigned to chemoradiation
with or without tirapazamine: a substudy of Trans-Tasman Radiation
Oncology Group study 98.02. J. Clin. Oncol. 2006, 24, 2098–2104.
21) Patterson, A. V.; Saunders, M. P.; Chinje, E. C.; Patterson, L. H.;
Stratford, I. J. Enzymology of tirapazamine metabolism: A review.
Anti-Cancer Drug Des. 1998, 13, 541–573.